Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
15M
Biotechnology
Next Earning date - 04 Aug 2025
15M
Biotechnology
Next Earning date - 04 Aug 2025
Relative Strenght
8Volume Buzz
-80%Earning Acce
NoDist 52w H.
88%